Related references
Note: Only part of the references are listed.EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies
Yijun Jia et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing
Patrick H. Lizotte et al.
CANCER RESEARCH (2018)
Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
Don-Hong Wang et al.
CLINICAL CANCER RESEARCH (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Dying cells actively regulate adaptive immune responses
Nader Yatim et al.
NATURE REVIEWS IMMUNOLOGY (2017)
PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Scott Gettinger et al.
CLINICAL CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Lung Cancer Subtypes Generate Unique Immune Responses
Stephanie E. Busch et al.
JOURNAL OF IMMUNOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
David G. McFadden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
Abhilash Venugopalan et al.
ONCOTARGET (2016)
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Kailong Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
A Distinct Function of Regulatory T Cells in Tissue Protection
Nicholas Arpaia et al.
CELL (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Creating reference gene annotation for the mouse C57BL6/J genome assembly
Jonathan M. Mudge et al.
MAMMALIAN GENOME (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Peter M. K. Westcott et al.
NATURE (2015)
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ping-Chih Ho et al.
CANCER RESEARCH (2014)
Intravascular staining for discrimination of vascular and tissue leukocytes
Kristin G. Anderson et al.
NATURE PROTOCOLS (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
Scott Joseph Antonia et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Erlotinib and Gefitinib, Epidermal Growth Factor Receptor Kinase Inhibitors, May Treat Non-Cancer-Related Tumor Necrosis Factor-α Mediated Inflammatory Diseases
Marvin B. Brooks
ONCOLOGIST (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
The alveolar macrophages in asthma: a double-edged sword
J. Balhara et al.
MUCOSAL IMMUNOLOGY (2012)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses
Thomas Krausgruber et al.
NATURE IMMUNOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway
Qiong Luo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2011)
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Katerina Politi et al.
DISEASE MODELS & MECHANISMS (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
Lucia Regales et al.
PLOS ONE (2007)
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Jeong M. Kim et al.
NATURE IMMUNOLOGY (2007)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Katerina Politi et al.
GENES & DEVELOPMENT (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effector function of human tumor-specific CD8 T cells in melanoma lesions:: A state of local functional tolerance
A Zippelius et al.
CANCER RESEARCH (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Control of effector CD8+ T cell function by the transcription factor Eomesodermin
EL Pearce et al.
SCIENCE (2003)
Share Paper
